Flash Player 9.0.0 is required for the Video Gallery. Get Adobe Flash Player.
Colleague's E-mail is Invalid
Your message has been successfully sent to your colleague.
Video Author: Akira Taguchi Published on: 10.22.2019 Associated with: Menopause. 26(11):1277-1283, November 2019
Bisphosphonate is the first line agent for osteoporosis, although We have been worried about the occurrence of severe adverse event associated with bisphosphonate on oral cavity, osteonecrosis of the jaws (ONJ). Also, periodontal disease, especially is the important risk factor for ONJ. The aim of this study was to determine whether once-yearly zoledronic acid in combination with proper self-oral hygiene management can improve symptomatic periodontal disease compared with placebo. Our results suggest that bisphosphonate use in combination of proper self-oral hygiene management for osteoporosis patients can prevent symptomatic periodontal disease, resulting in the risk reduction of bisphosphonate-related ONJ.
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. For information on cookies and how you can disable them visit our Privacy and Cookie Policy.